Morgan Stanley raised the firm’s price target on Medacta Group (MEDGF) to CHF 146 from CHF 136 and keeps an Overweight rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDGF:
- Medacta Group SA Reports Strong 2024 Financial Growth
- Medacta Group SA Achieves Robust Growth in 2024 with Innovative Orthopedic Solutions
- Medacta Group SA: Strong Financial Performance and Growth Potential Justify Buy Rating
- Medacta Group price target raised to CHF 160 from CHF 150 at Berenberg
- Medacta Group price target raised to CHF 136 from CHF 135 at Morgan Stanley